{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:21:23Z","timestamp":1788182483972,"version":"build-2803163510"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Several studies have demonstrated the safety and efficacy of sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i), but there is little evidence on how these drugs improve cardiac remodeling parameters in patients with heart failure (HF). We performed a meta-analysis of RCTs to evaluate the effect of SGLT2i on cardiac remodeling in patients with HF. The study protocol was registered in June 2025 (PROSPERO: CRD420251055562).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The Medline, Scopus, and Cochrane Central databases were searched for RCTs that compared SGLT2i with placebo in patients \u226518 years of age with a diagnosis of HF. Eleven outcomes were analyzed, including left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVES), left ventricular mass (LVM), left ventricular ejection fraction (LVEF), left atrial volume indexed (LAVi), left ventricular global longitudinal Strain, stroke volume, and E\/e\u2019. Statistical analyses were performed using R version 4.3.2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 13 RCTs with 1181 patients, 592 of whom received SGLT2i as the intervention. LVEDV (MD: \u22128.41 mL; 95% CI: \u221213.07 to \u2212 3.75,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), LVES (MD: \u22128.11 mL; 95% CI: \u221213.95 to \u22122.28,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0,006), left ventricular end-systolic volume indexed (LVESVi) (MD: \u22123.71 mL\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 95% CI: \u22126.84 to \u2212 0.58,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), LVM (MD: \u22127.65 g; 95% CI: \u221213.79 to \u22121.51,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), and LAVi (MD: \u22122.04 ml\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 95% CI: \u22123.21 to \u2212 0.86,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0007) were significantly lower in patients treated with SGLT2i compared to placebo. In addition, this treatment led to a significant increase in LVEF (MD: +2.59%, 95% CI: 1.76 to 3.43,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001) compared to placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results suggest that in patients with HF, SGLT2i have a positive influence on cardiac remodeling since they lead to a significant decrease in LVEDV, LVES, LVESVi, LVM, left ventricular mass indexed, and LAVi compared to placebo and a significant increase in EF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcecho.jcecho_11_26","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:00:45Z","timestamp":1784559645000},"page":"395-407","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Imaging-based Demonstration of Reverse Left Heart Remodeling after Sodium\u2013Glucose Co-transporter 2 Inhibitors in Heart Failure: A Systematic Review and Meta-analysis"],"prefix":"10.4103","volume":"36","author":[{"given":"Federico","family":"Giannino","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Colarusso","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio Cusm\u00e0","family":"Piccione","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society Of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-20260831","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: A step ahead in an improved pathological understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: A systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/ehf2.14993","article-title":"Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis","volume":"11","author":"Savage","year":"2024","journal-title":"ESC Heart Fail"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"106243","DOI":"10.1016\/j.phrs.2022.106243","article-title":"The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis","volume":"180","author":"Theofilis","year":"2022","journal-title":"Pharmacol Res"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: An updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/09622802231172043","article-title":"Detecting the skewness of data from the five-number summary and its application in meta-analysis","volume":"32","author":"Shi","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res Synth Methods"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R20-20260831","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect","author":"Higgins","year":"2024","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"key":"R21-20260831","article-title":"Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024)","author":"Deeks","year":"2024","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00228-024-03643-3","article-title":"DAHOS study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome \u2013 A 3-month, multicenter, randomized controlled clinical trial","volume":"80","author":"Xie","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jcmg.2024.05.014","article-title":"Dapagliflozin effects on cardiac deformation in heart failure and secondary clinical Outcome","volume":"17","author":"Pastore","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: The DAPA-LVH trial","volume":"41","author":"Brown","year":"2020","journal-title":"Eur Heart J"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12872-023-03591-3","article-title":"Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.124.069144","article-title":"Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT trial","volume":"149","author":"Kang","year":"2024","journal-title":"Circulation"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized Trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: The REFORM trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.15296","article-title":"Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial","volume":"12","author":"Huang","year":"2025","journal-title":"ESC Heart Fail"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ggi.14363","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study","volume":"22","author":"Akasaka","year":"2022","journal-title":"Geriatr Gerontol Int"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: The randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/00015385.2023.2240130","article-title":"Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction","volume":"79","author":"Afshani","year":"2024","journal-title":"Acta Cardiol"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0735-1097(03)00789-7","article-title":"The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure","volume":"42","author":"Curtis","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R36-20260831","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"R37-20260831","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R38-20260831","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"R39-20260831","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN echo substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"R40-20260831","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R41-20260831","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"R42-20260831","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"R43-20260831","doi-asserted-by":"crossref","first-page":"1291450","DOI":"10.3389\/fcvm.2023.1291450","article-title":"The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy","volume":"10","author":"Su","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R44-20260831","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"R45-20260831","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jacc.2005.08.077","article-title":"Prediction of cardiovascular outcomes with left atrial size: Is volume superior to area or diameter?","volume":"47","author":"Tsang","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R46-20260831","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2006.02.048","article-title":"Left atrial size: Physiologic determinants and clinical applications","volume":"47","author":"Abhayaratna","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R47-20260831","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0735-1097(02)02981-9","article-title":"Left atrial volume as an index of left atrial size: A population-based study","volume":"41","author":"Pritchett","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R48-20260831","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R49-20260831","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"R50-20260831","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/01.CIR.102.15.1788","article-title":"Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study","volume":"102","author":"Ommen","year":"2000","journal-title":"Circulation"},{"key":"R51-20260831","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.echo.2015.06.011","article-title":"Head-to-head comparison of global longitudinal strain measurements among nine different vendors: The EACVI\/ASE inter-vendor comparison study","volume":"28","author":"Farsalinos","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"R52-20260831","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10741-015-9520-9","article-title":"Left atrial strain: A new parameter for assessment of left ventricular filling pressure","volume":"21","author":"Cameli","year":"2016","journal-title":"Heart Fail Rev"},{"key":"R53-20260831","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jcmg.2016.08.014","article-title":"LA strain for categorization of LV diastolic dysfunction","volume":"10","author":"Singh","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"R54-20260831","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R55-20260831","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"key":"R56-20260831","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"R57-20260831","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"R58-20260831","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","article-title":"Diabetic cardiomyopathy: Definition, diagnosis, and therapeutic implications","volume":"15","author":"Paolillo","year":"2019","journal-title":"Heart Fail Clin"}],"container-title":["Journal of Cardiovascular Echography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcecho.jcecho_11_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:01:11Z","timestamp":1788181271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcecho.jcecho_11_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcecho.jcecho_11_26","relation":{},"ISSN":["2211-4122","2347-193X"],"issn-type":[{"value":"2211-4122","type":"print"},{"value":"2347-193X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"2026-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}